262 related articles for article (PubMed ID: 27500470)
21. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
22. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
23. CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status.
Sellar RS; Vargas FA; Henry JY; Verfuerth S; Charrot S; Beaton B; Chakraverty R; Quezada SA; Mackinnon S; Thomson KJ; Peggs KS
Blood; 2015 Jan; 125(4):731-9. PubMed ID: 25499763
[TBL] [Abstract][Full Text] [Related]
24. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model.
Ploemacher RE; Johnson KW; Rombouts EJ; Etienne K; Westerhof GR; Baumgart J; White-Scharf ME; Down JD
Biol Blood Marrow Transplant; 2004 Apr; 10(4):236-45. PubMed ID: 15077222
[TBL] [Abstract][Full Text] [Related]
25. Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach.
Sasaki H; Oura T; Spitzer TR; Chen YB; Madsen JC; Allan J; Sachs DH; Cosimi AB; Kawai T
Hum Immunol; 2018 May; 79(5):258-265. PubMed ID: 29175110
[TBL] [Abstract][Full Text] [Related]
26. Combinations of anti-LFA-1, everolimus, anti-CD40 ligand, and allogeneic bone marrow induce central transplantation tolerance through hemopoietic chimerism, including protection from chronic heart allograft rejection.
Metzler B; Gfeller P; Bigaud M; Li J; Wieczorek G; Heusser C; Lake P; Katopodis A
J Immunol; 2004 Dec; 173(11):7025-36. PubMed ID: 15557200
[TBL] [Abstract][Full Text] [Related]
27. Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts.
Gammie JS; Li S; Zeevi A; Demetris AJ; Ildstad ST; Pham SM
Circulation; 1998 Nov; 98(19 Suppl):II163-8; discussion II168-9. PubMed ID: 9852899
[TBL] [Abstract][Full Text] [Related]
28. Optimizing chimerism level through bone marrow transplantation and irradiation to induce long-term tolerance to composite tissue allotransplantation.
Lin JY; Tsai FC; Wallace CG; Huang WC; Wei FC; Liao SK
J Surg Res; 2012 Nov; 178(1):487-93. PubMed ID: 22484382
[TBL] [Abstract][Full Text] [Related]
29. Hematopoietic chimerism induces renal and skin allograft tolerance in DLA-identical dogs.
Tillson M; Niemeyer GP; Welch JA; Brawner W; Swaim SF; Rynders P; Lenz SD; Dean B; Lothrop CD
Exp Hematol; 2006 Dec; 34(12):1759-70. PubMed ID: 17157174
[TBL] [Abstract][Full Text] [Related]
30. Innate and adaptive immune responses are tolerized in chimeras prepared with nonmyeloablative conditioning.
Xu H; Zhu Z; Huang Y; Bozulic LD; Hussain LR; Yan J; Ildstad ST
Transplantation; 2012 Mar; 93(5):469-76. PubMed ID: 22228418
[TBL] [Abstract][Full Text] [Related]
31. Mixed allogeneic chimerism in the rat. Donor-specific transplantation tolerance without chronic rejection for primarily vascularized cardiac allografts.
Colson YL; Zadach K; Nalesnik M; Ildstad ST
Transplantation; 1995 Nov; 60(9):971-80. PubMed ID: 7491703
[TBL] [Abstract][Full Text] [Related]
32. Engraftment of quiescent progenitors and conversion to full chimerism after nonmyelosuppressive conditioning and hematopoietic cell transplantation in miniature swine.
Lima B; Gleit ZL; Cameron AM; Germana S; Murphy MC; Consorti R; Chang Q; Down JD; LeGuern C; Sachs DH; Huang CA
Biol Blood Marrow Transplant; 2003 Sep; 9(9):571-82. PubMed ID: 14506659
[TBL] [Abstract][Full Text] [Related]
33. Chimerism-Based Tolerance to Kidney Allografts in Humans: Novel Insights and Future Perspectives.
Podestà MA; Sykes M
Front Immunol; 2021; 12():791725. PubMed ID: 35069574
[TBL] [Abstract][Full Text] [Related]
34. Combined treatment with regulatory T cells and vascularized bone marrow transplantation creates mixed chimerism and induces donor-specific tolerance to vascularized composite allografts without cytoreductive conditioning.
Lin JY; Tsai FC; Wallace CG; Huang WC; Wei FC; Liao SK
J Surg Res; 2012 Dec; 178(2):974-81. PubMed ID: 22819314
[TBL] [Abstract][Full Text] [Related]
35. Failure of chimerism formation and tolerance induction from Fas ligand mutant bone marrow donors after nonmyeloablative conditioning.
Nusair S; Gincberg G; Almogi-Hazan O; Breuer R; Or R; Wallach-Dayan SB
Transpl Immunol; 2012 Dec; 27(4):184-8. PubMed ID: 22801052
[TBL] [Abstract][Full Text] [Related]
36. Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade.
Foster RD; Pham S; Li S; Aitouche A
Transplantation; 2003 Sep; 76(6):988-94. PubMed ID: 14508367
[TBL] [Abstract][Full Text] [Related]
37. Overcoming memory T-cell responses for induction of delayed tolerance in nonhuman primates.
Yamada Y; Boskovic S; Aoyama A; Murakami T; Putheti P; Smith RN; Ochiai T; Nadazdin O; Koyama I; Boenisch O; Najafian N; Bhasin MK; Colvin RB; Madsen JC; Strom TB; Sachs DH; Benichou G; Cosimi AB; Kawai T
Am J Transplant; 2012 Feb; 12(2):330-40. PubMed ID: 22053723
[TBL] [Abstract][Full Text] [Related]
38. Immune Reconstitution Kinetics following Intentionally Induced Mixed Chimerism by Nonmyeloablative Transplantation.
Kim N; Lee H; Shin J; Nam YS; Im KI; Lim JY; Lee ES; Kang YN; Park SH; Cho SG
PLoS One; 2015; 10(5):e0126318. PubMed ID: 25961559
[TBL] [Abstract][Full Text] [Related]
39. Chimerism-based tolerance in organ transplantation: preclinical and clinical studies.
Oura T; Cosimi AB; Kawai T
Clin Exp Immunol; 2017 Aug; 189(2):190-196. PubMed ID: 28369830
[TBL] [Abstract][Full Text] [Related]
40. Targeting cells causing split tolerance allows fully allogeneic islet survival with minimal conditioning in NOD mixed chimeras.
Al-Adra DP; Pawlick R; Shapiro AM; Anderson CC
Am J Transplant; 2012 Dec; 12(12):3235-45. PubMed ID: 22974315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
